Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Apr;9(2):406-409.
doi: 10.21037/tlcr.2020.02.06.

Anti-PDL1 effect in squamous non-small cell lung cancer

Mohamed Rahouma  1   2 , Massimo Baudo  2 , Mohamed Kamel  1   2 , Nagla Abdel Karim  3 , Nasser Altorki  2
Affiliations
Editorial

Anti-PDL1 effect in squamous non-small cell lung cancer

Mohamed Rahouma et al. Transl Lung Cancer Res. 2020 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr.2020.02.06). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Depiction of cell receptors found on T-cells and cancer cells: PD-1 and CTLA-4 inhibit T-cell activation (“‒” sign), while CD-28 and TCR activate T-Cells (“+” sign). CTLA-4, cytotoxic T-lymphocyte antigen 4; MHC, major histocompatibility complex; PD-1, programmed death receptor 1; PD-L1, programmed death receptor ligand 1; TCR, T-cell receptor.
See this image and copyright information in PMC

Comment on

  • Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
    Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Paz-Ares L, et al. N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280635 Clinical Trial.

References

    1. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6. 10.1126/science.271.5256.1734 - DOI - PubMed
    1. FDA Approves YERVOYTM (ipilimumab) for the Treatment of Patients with Newly Diagnosed or Previously-Treated Unresectable or Metastatic Melanoma, the Deadliest Form of Skin Cancer. (accessed January 8, 2020). Available online: https://news.bms.com/press-release/rd-news/fda-approves-yervoy-ipilimuma...
    1. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34. 10.1084/jem.192.7.1027 - DOI - PMC - PubMed
    1. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:123-35. 10.1056/NEJMoa1504627 - DOI - PMC - PubMed
    1. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50. 10.1016/S0140-6736(15)01281-7 - DOI - PubMed